The 2018 Annual Report of Cancer Drug Resistance
Since the first issue of Cancer Drug Resistance (CDR) was officially published on March 19, 2018, more and more scientists pay attention to this journal and are inspired by the journal’s achievement throughout the year. In 2018, CDR published a total of 20 papers, which have been cited 21 times (by Google Scholar)/14 times (by Crossref) within this year. With the continuous support of scientists worldwide, 7 Special Issues on topics such as "Pharmacogenetics of Cancer", "Non-coding RNAs in Response and Resistance to Therapy in Cancer", "Drug Resistance Mechanisms in Cancer", etc. are open for submission. The Special Issues in 2018 were particularly successful, which have broadened the understanding of experts in the field. We are pleased that some international conferences (including GRC, BACR, etc.) offered CDR support and all Editorial Board members are fully involved in contributing to CDR. By the end of 2018, we would like to express our gratitude to all contributors and are pleased to use this opportunity to show the progress of the journal.
1．Editorial Board
Editor-in-Chief: Prof. Godefridus J. Peters
Editorial Board Members: 28 (from VU University Medical Center, Roswell Park Cancer Institute, Fondazione IRCCS Istituto Nazionale Tumori, etc.)
In 2018, we would like to thank all the Editorial Board members for their kind suggestions on the orientation of journal development and continuous support to CDR.
2．Papers
In 2018, CDR has totally received 47 submissions.
- Published Papers: 20
- Rejected Papers: 5
- Under Processing: 22
- Percentage of Rejection: 11%
A List of Authors by Country/Region:
A List of Published Papers by Article Type:
Article Processing Time (from Submission to Publication):
| Article No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Month | February | March | May | July | August | September | October | November | December | |||||||||||
| Processing Time (PT)/days | 48 | 58 | 49 | 7 | 41 | 79 | 4 | 53 | 30 | 64 | 54 | 57 | 83 | 83 | 21 | 23 | 70 | 110 | 75 | 16 |
| Average Processing Time (APT)/days | 51.3 | |||||||||||||||||||
Views, Downloads and Citations (Total):
| Views (by Google) | Views (by Google) | Citations (by Crossref) | |
|---|---|---|---|
| Total | 36,963 | 2,072 | 14 |
Views, Downloads and Citations (Top Six):
| No. | Title | Corresponding Author | Views (by Google) | Downloads (by Google) | Citation (by Crossref) |
|---|---|---|---|---|---|
| 1 | How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance? | Gerrit Jansen; Godefridus J. Peters | 3848 | 188 | 7 |
| 2 | Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer | Elisa Giovannetti | 1300 | 91 | 2 |
| 3 | Cancer drug resistance: a new perspective | Godefridus J. Peters | 5077 | 339 | 2 |
| 4 | Sphingolipid metabolism and drug resistance in ovarian cancer | Karina J. Yoon | 4068 | 177 | 1 |
| 5 | Targeted therapies in cancer: where are we going? | Elisa Giovannetti | 1742 | 134 | 1 |
| 6 | Reduction of mitomycin C resistance in human bladder cancer T24 cells by knocking-down ras oncogene | Abdel-Motaal Fouda | 3072 | 98 | 1 |
3．Readership
4．Special Issues
In 2018, CDR organized 7 Special Issues on hot topics of cancer drug resistance.
| Special Issue | Guest Editors | Submission Deadline | Published Papers | Manuscript(s) Under Processing |
|---|---|---|---|---|
| 1. Targeted Cancer Therapy | Dr. Elisa Giovannetti Dr. Jose Antonio Rodriguez | 3 Sept 2018 | 7 | / |
| Special Issue | Guest Editors | Submission Deadline | Manuscripts Pending Submission | Manuscript(s) Under Processing/Published |
| 2. Pharmacogenetics of Cancer | Prof. Enrico Mini Dr. Stefania Nobili | 31 Oct 2018 | 10 | 12 |
| 3. Epigenetic Basis of Cancer Drug Resistance | Dr. Aamir Ahmad | 20 Dec 2018 | 18 | 5/1 |
| 4. Papers from the BACR Conference-Response and Resistance in Cancer Therapy | Dr. Tim Fenton Prof. Michelle Garrett Prof. Martin Michaelis Dr. Mark Wass | 20 Dec 2018 | / | 2/2 |
| 5. Drug Resistance Mechanisms in Cancer | Dr. Helen M. Coley | 31 Mar 2019 | 66 | 3 |
| 6. Non-coding RNAs in Response and Resistance to Therapy in Cancer | Prof. Francois-Xavier Claret Dr. José Rueff | 30 Jun 2019 | 11 | / |
| 7. Drug Resistance and Cancer Stem Cell | Dr. Miroslav Blumenberg | 30 Apr 2019 | / | / |
5．Promotion of the Journal
We are honored that the following conferences allowed some of our EBMs to promote CDR during the meetings.
 | (1)The 2018 Gordon Research Conference on Drug Resistance Time and Venue: July 22-27, 2018, Smithfield, Rhode Island, United States Website: https://www.grc.org/drug-resistance-conference/2018/ |
| (2)The 2018 Gordon Research Conference on Personalized Medicine Time and Venue: July 22-27, 2018, Smithfield, Rhode Island, United States Website: https://www.grc.org/personalized-medicine-conference/2018/ | |
| (3)The 2018 Gordon Research Conference on DNA Topoisomerases in Biology and Medicine Time and Venue:July 29–August 3, 2018. Mount Holyoke College, 50 College Street, South Hadley, MA, United States Website: https://www.grc.org/dna-topoisomerases-in-biology-and-medicine-conference/2018/ | |
 | (4)The BACR Special Conference "Response and Resistance in Cancer Therapy" Time and Venue:September 10-12, 2018, University of Kent, Canterbury, United Kingdom |
Finally, we thank all the scientists for their interest and support in CDR throughout the year. Cancer Drug Resistance aims to be a high-quality academic journal in cancer drug resistance and is preparing for the evaluation for indexing in some well-recognized databases like PubMed, SCI, etc. within a few years. For instance, the journal is already indexed in Google Scholar. Your understanding and continuous support are cornerstone for our progress. We are convinced that Cancer Drug Resistance will grow into a leading journal of this field in the near future.
